GlassScriptPhysician profile
Mitchel Norton
NPI 1073047957
$1,206.54
in general payments reported to CMS, 2019-2025
20 companies · $739 in 2025
The $739 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $87.52 · 2024: $380 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $173.12 | 2024-2025 | |
| Lundbeck LLC | $158.89 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $145.40 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.79 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $101.32 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $62.28 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $61.14 | 2025 | Breztri |
| Abbvie INC. | $59.47 | 2024-2025 | |
| Lilly USA, LLC | $46.74 | 2023-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $46.00 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $36.36 | 2023-2025 | Dificid, Vaxelis, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.53 | 2025 | Jardiance |
| Viatris Specialty LLC | $32.44 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $28.12 | 2024 | |
| Astellas Pharma US INC | $27.33 | 2025 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $19.10 | 2025 | Zenpep |
| Glaxosmithkline, LLC. | $17.25 | 2025 | Bexsero |
| Ironshore Pharmaceuticals INC. | $15.75 | 2023 | Jornay Pm |
| Currax Pharmaceuticals LLC | $13.54 | 2024 | Contrave |
| Organon LLC | $9.97 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchel Norton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.